The SCRIPT pilot project

๐ŸŒฟ๐—–๐—ฒ๐—น๐—ฒ๐—ฏ๐—ฟ๐—ฎ๐˜๐—ถ๐—ป๐—ด ๐—”๐—ป๐—ผ๐˜๐—ต๐—ฒ๐—ฟ ๐— ๐—ฎ๐—ท๐—ผ๐—ฟ ๐— ๐—ถ๐—น๐—ฒ๐˜€๐˜๐—ผ๐—ป๐—ฒ ๐—ถ๐—ป ๐—–๐—ฎ๐—ป๐—ป๐—ฎ๐—ฏ๐—ถ๐˜€ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต: ๐—ง๐—ต๐—ฒ ๐—ฆ๐—–๐—ฅ๐—œ๐—ฃ๐—ง ๐—ฃ๐—ถ๐—น๐—ผ๐˜ ๐—ฃ๐—ฟ๐—ผ๐—ท๐—ฒ๐—ฐ๐˜๐ŸŒฟ

๐ŸŽ‰We are thrilled to announce another significant milestone in THC cannabis research. Pure Production AG, a member of the Pure Group, is the exclusive cannabis producer for the groundbreaking SCRIPT pilot project.

๐Ÿ”ฌ๐—”๐—ฏ๐—ผ๐˜‚๐˜ ๐—ฆ๐—–๐—ฅ๐—œ๐—ฃ๐—ง: The “Safer Cannabis Research In Pharmacies randomized controlled Trial” (SCRIPT), spearheaded by the University of Bern in collaboration with the University of Lucerne and the cities of Bern, Biel, and Lucerne, has been greenlit by Swiss health and ethics authorities. This study, starting in autumn 2023, is not just a research initiative but a step forward in understanding the health and social impacts of regulated cannabis sales.

๐Ÿ›๏ธ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—–๐—ผ๐—ป๐˜๐—ฒ๐˜…๐˜: SCRIPT is a vital part of the Swiss government’s exploratory efforts under the revised narcotics law that permits controlled non-medical cannabis distribution studies. It uniquely focuses on a non-profit model with cannabis sourced from Switzerland under organic regulations, highlighting our commitment to quality and regulatory compliance.

๐Ÿ‘ฅ ๐—ฆ๐˜๐˜‚๐—ฑ๐˜† ๐—ฆ๐—ฐ๐—ผ๐—ฝ๐—ฒ: Set in Bern, Biel, and Lucerne, SCRIPT aims to involve about 1,000 regular recreational cannabis users over 18. The randomized control approach, wherein only half the participants can buy regulated cannabis products from pharmacies in the first six months, ensures reliable data. This method, along with the study’s emphasis on public health, youth protection, and public safety, distinguishes SCRIPT from other pilot projects.

๐Ÿ’ก๐—œ๐—ป๐—ป๐—ผ๐˜ƒ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ถ๐—ป ๐—”๐—ฐ๐˜๐—ถ๐—ผ๐—ป: Participants will have access to various cannabis products, including flowers, hashish, e-liquids, and tinctures, all produced in Switzerland by Pure Production AG and Puregene AG under stringent quality controls and bio-regulations. This initiative not only showcases our dedication to quality and innovation but also emphasizes our role in shaping the future of cannabis in Europe.

๐ŸŒฑ ๐—ฃ๐˜‚๐—ฟ๐—ฒ ๐—š๐—ฟ๐—ผ๐˜‚๐—ฝ’๐˜€ ๐—ฅ๐—ผ๐—น๐—ฒ: As Europe’s first legal recreational THC cannabis producer, Pure Production AG is proud to contribute to this innovative study. Our journey from ‘Seed to Sale’ reflects our dedication to pioneering cannabis research, cultivation, and distribution. We are honored to play a pivotal role in SCRIPT, supporting efforts to inform future cannabis regulations and improve public health and safety.

๐ŸŒ For more information on the SCRIPT study, visit the official website: https://www.script-studie.ch/
Forbes
Nau media AG